News

not found

Fresh WHO alert on 'contaminated' Indian cough syrup

The World Health Organization (WHO) on Monday issued a global alert regarding an Indian-made cough syrup called "Cold Out," which is being sold in Iraq. The medication was found to be contaminated with toxins. "The substandard batch of the product is unsafe and its use, especially in children, may result in serious injury or death," the alert warned. This is the fifth such warning being issued against an Indian pharmaceutical manufacturer in the past 10 months. Alert on toxins and its effects The syrup was manufactured by Fourrts (India) Laboratories for Dabilife Pharma and it contained contaminants higher than the acceptable level, said the WHO. However, Bala Surendran, the vice president of the company, told Bloomberg news last month that the production of the medicine had been subcontracted to another company and that his company had not found any toxins in a sample they had reviewed. The batch of syrup found on the Iraqi market had 0.25% of diethylene glycol and 2.1% of ethylene glycol. The acceptable safety limit for both is up to 0.10%, the WHO said. The agency added that the manufacturer and marketer have not provided guarantees to the WHO on the safety and quality of the product. The WHO listed the "toxic effects" of the syrup as "abdominal pain, vomiting, diarrhea, inability to pass urine, headache, altered mental state and acute kidney injury which may lead to death." The Ministry of Health in India announced that after the medicine failed separate tests conducted in Iraq, products were now being confiscated from the market, reported Bloomberg.

  • 9 August, 08:55
  • Read more
not found

Tuberculosis vaccines were created 100 years ago and they are not up to the demand - the head of WHO

The World Health Organization intends to create a Council for the accelerated development of vaccines against tuberculosis. This was announced at the World Economic Forum in Davos by WHO Director-General Tedros Adhanom Ghebreyesus, the UN press service reports. The Council will help to overcome barriers to the development of new TB vaccines, as well as their licensing and early use.  "One of the most important lessons of the COVID-19 pandemic is that innovative health interventions are only taken quickly if they are given political priority and adequate funding," Ghebreyesus said. While countries have made bold commitments to end TB by 2030 as part of the Sustainable Development Goals, the epidemic shows no signs of slowing down. In 2021, approximately 10.6 million people fell ill with tuberculosis and 1.6 million died. Currently, the only licensed TB vaccine in the world is BCG, developed more than a hundred years ago. It is moderately effective in preventing severe disease in infants and young children, but fails to provide adequate protection for adolescents and adults, who account for about 90 per cent of TB transmission worldwide. A recent WHO study estimates that if a new vaccine is effective in 50 percent of cases, up to 76 million new TB cases, 8.5 million deaths, 42 million antibiotic treatments, and $6.5 billion in costs could be prevented within 25 years. If a vaccine is developed with 75 percent efficacy, 110 million new TB infections and 12.3 million deaths could be prevented in the same time.

  • 7 August, 17:15
  • Read more
Нажмите на кнопку ниже, чтобы прослушать текст Powered by GSpeech